CL2019000778A1 - Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso. - Google Patents
Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso.Info
- Publication number
- CL2019000778A1 CL2019000778A1 CL2019000778A CL2019000778A CL2019000778A1 CL 2019000778 A1 CL2019000778 A1 CL 2019000778A1 CL 2019000778 A CL2019000778 A CL 2019000778A CL 2019000778 A CL2019000778 A CL 2019000778A CL 2019000778 A1 CL2019000778 A1 CL 2019000778A1
- Authority
- CL
- Chile
- Prior art keywords
- disorders
- mglur2
- same
- vehicle
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
- A61K31/015—Hydrocarbons carbocyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA CIERTOS COMPUESTOS DE CROMANO, ISOCROMANO Y DIHIDROISOBENZOFURANO SUSTITUIDOS DE FÓRMULA (I), O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS, EN LA QUE EL ANILLO A ES UN RESTO SELECCIONADO DE, Y EL ANILLO B, N, R1 , R2 , R2A, R3 Y R3A SON COMO SE DEFINEN EN LA PRESENTE MEMORIA. LOS COMPUESTOS DE LA INVENCIÓN SON ÚTILES COMO INHIBIDORES DE MGLUR2, O MODULADORES ALOSTÉRICOS NEGATIVOS DE MGLUR2 (NAM), Y PUEDEN SER ÚTILES EN PROCEDIMIENTOS DE TRATAMIENTO DE UN PACIENTE PARA ENFERMEDADES O TRASTORNOS EN LOS QUE ESTÁ IMPLICADO EL RECEPTOR MGLUR2-NAM, TALES COMO LA ENFERMEDAD DE ALZHEIMER, DETERIORO COGNITIVO, DETERIORO COGNITIVO LEVE, ESQUIZOFRENIA Y OTROS TRASTORNOS DEL ESTADO DE ÁNIMO, TRASTORNOS DEL DOLOR Y TRASTORNOS DEL SUEÑO, MEDIANTE LA ADMINISTRACIÓN AL PACIENTE DE UNA CANTIDAD TERAPÉUTICAMENTE EFICAZ DE UN COMPUESTO DE LA INVENCIÓN, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO. LA INVENCIÓN TAMBIÉN SE REFIERE A COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN UN COMPUESTO DE LA INVENCIÓN, O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO, (OPCIONALMENTE EN COMBINACIÓN CON UNO O MÁS INGREDIENTES ACTIVOS ADICIONALES), Y UN VEHÍCULO FARMACÉUTICAMENTE ACEPTABLE, Y AL USO DE LOS COMPUESTOS Y COMPOSICIONES FARMACÉUTICAS DE LA INVENCIÓN EN EL TRATAMIENTO DE TALES ENFERMEDADES.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662400150P | 2016-09-27 | 2016-09-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019000778A1 true CL2019000778A1 (es) | 2019-05-31 |
Family
ID=60043302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000778A CL2019000778A1 (es) | 2016-09-27 | 2019-03-25 | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso. |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US10335399B2 (es) |
| EP (1) | EP3519416B1 (es) |
| JP (3) | JP6681517B2 (es) |
| KR (1) | KR102296043B1 (es) |
| CN (1) | CN109983022B (es) |
| AR (1) | AR109714A1 (es) |
| AU (2) | AU2017334870C1 (es) |
| CA (1) | CA3037537C (es) |
| CL (1) | CL2019000778A1 (es) |
| CO (1) | CO2019002673A2 (es) |
| CR (1) | CR20190147A (es) |
| CY (1) | CY1124346T1 (es) |
| DK (1) | DK3519416T3 (es) |
| DO (1) | DOP2019000076A (es) |
| EA (1) | EA038627B1 (es) |
| EC (1) | ECSP19020742A (es) |
| ES (1) | ES2868973T3 (es) |
| GE (2) | GEP20217279B (es) |
| HR (1) | HRP20210793T1 (es) |
| HU (1) | HUE054898T2 (es) |
| IL (1) | IL265366B (es) |
| JO (1) | JOP20190058B1 (es) |
| LT (1) | LT3519416T (es) |
| MA (1) | MA46342B1 (es) |
| MD (1) | MD3519416T2 (es) |
| MX (1) | MX2019003492A (es) |
| MY (1) | MY196807A (es) |
| NI (1) | NI201900025A (es) |
| PE (1) | PE20190609A1 (es) |
| PH (1) | PH12019500597A1 (es) |
| PL (1) | PL3519416T3 (es) |
| PT (1) | PT3519416T (es) |
| RS (1) | RS61890B1 (es) |
| SI (1) | SI3519416T1 (es) |
| TN (2) | TN2020000161A1 (es) |
| TW (1) | TWI764934B (es) |
| UA (1) | UA123687C2 (es) |
| WO (1) | WO2018063955A1 (es) |
| ZA (1) | ZA201901701B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA038627B1 (ru) * | 2016-09-27 | 2021-09-24 | Мерк Шарп И Доум Корп. | ПРОИЗВОДНЫЕ ХРОМАНА, ИЗОХРОМАНА И ДИГИДРОИЗОБЕНЗОФУРАНА В КАЧЕСТВЕ НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2, ИХ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ |
| CA3087283A1 (en) | 2018-01-19 | 2019-07-25 | Cytokinetics, Inc. | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| KR102704291B1 (ko) * | 2019-03-01 | 2024-09-09 | 노보 노르디스크 에이/에스 | 융합 3환 화합물의 제조 방법, 및 그의 중간체 |
| MX2023010125A (es) | 2021-03-04 | 2023-09-11 | Cytokinetics Inc | Inhibidores del sarcomero cardiaco. |
| WO2023278729A1 (en) * | 2021-06-30 | 2023-01-05 | The General Hospital Corporation | Chromane imaging ligands |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5552437A (en) | 1994-10-27 | 1996-09-03 | Merck Frosst Canada, Inc. | Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis |
| US5576338A (en) | 1995-02-15 | 1996-11-19 | Merck Frosst Canada, Inc. | Bis (biaryl) compounds as inhibitors of leukotriene biosynthesis |
| WO2005014543A1 (ja) | 2003-08-06 | 2005-02-17 | Japan Tobacco Inc. | 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用 |
| CA2624294A1 (en) | 2005-10-05 | 2007-04-12 | Merck Frosst Canada Ltd. | Substituted quinolines as inhibitors of leukotriene biosynthesis |
| AR065093A1 (es) | 2007-02-05 | 2009-05-13 | Merck Frosst Canada Ltd | Compuestos farmacéuticos inhibidores de la biosintesis de leucotrienos |
| WO2010021693A2 (en) | 2008-08-18 | 2010-02-25 | Yale University | Mif modulators |
| MY161325A (en) * | 2009-05-12 | 2017-04-14 | Janssen Pharmaceuticals Inc | 1, 2, 4-triazolo[4,3-a]pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
| WO2011075699A2 (en) | 2009-12-18 | 2011-06-23 | Sunovion Pharmaceuticals Inc. | Compounds for treating disorders mediated by metabotropic glutamate receptor 5, and methods of use thereof |
| WO2013066736A1 (en) * | 2011-11-03 | 2013-05-10 | Merck Sharp & Dohme Corp. | QUINOLINE CARBOXAMIDE AND QUINOLINE CARBONITRILE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| WO2016029454A1 (en) | 2014-08-29 | 2016-03-03 | Merck Sharp & Dohme Corp. | TETRAHYDRONAPHTHYRIDINE DERIVATIVES AS mGluR2-NEGATIVE ALLOSTERIC MODULATORS, COMPOSITIONS, AND THEIR USE |
| US9382208B1 (en) | 2015-01-26 | 2016-07-05 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| WO2016149324A1 (en) | 2015-03-16 | 2016-09-22 | Vanderbilt University | Negative allosteric modulators of metabotropic glutamate receptor 2 |
| JP6471614B2 (ja) | 2015-05-29 | 2019-02-20 | 株式会社リコー | 通信端末、通信システム、通信制御方法、及びプログラム |
| JP2018154554A (ja) | 2015-07-29 | 2018-10-04 | 大日本住友製薬株式会社 | 新規リンカー部位を持つ縮合ピラゾール誘導体およびその医薬用途 |
| EA038627B1 (ru) * | 2016-09-27 | 2021-09-24 | Мерк Шарп И Доум Корп. | ПРОИЗВОДНЫЕ ХРОМАНА, ИЗОХРОМАНА И ДИГИДРОИЗОБЕНЗОФУРАНА В КАЧЕСТВЕ НЕГАТИВНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2, ИХ КОМПОЗИЦИИ И ПРИМЕНЕНИЕ |
-
2017
- 2017-09-25 EA EA201990818A patent/EA038627B1/ru unknown
- 2017-09-25 TW TW106132824A patent/TWI764934B/zh active
- 2017-09-25 UA UAA201904545A patent/UA123687C2/uk unknown
- 2017-09-25 CN CN201780071759.0A patent/CN109983022B/zh active Active
- 2017-09-25 JO JOP/2019/0058A patent/JOP20190058B1/ar active
- 2017-09-25 ES ES17781253T patent/ES2868973T3/es active Active
- 2017-09-25 MD MDE20190867T patent/MD3519416T2/ro unknown
- 2017-09-25 GE GEAP201715310A patent/GEP20217279B/en unknown
- 2017-09-25 GE GEAP201715056A patent/GEP20217266B/en unknown
- 2017-09-25 WO PCT/US2017/053155 patent/WO2018063955A1/en active Application Filing
- 2017-09-25 TN TNP/2020/000161A patent/TN2020000161A1/en unknown
- 2017-09-25 EP EP17781253.4A patent/EP3519416B1/en active Active
- 2017-09-25 PL PL17781253T patent/PL3519416T3/pl unknown
- 2017-09-25 DK DK17781253.4T patent/DK3519416T3/da active
- 2017-09-25 PE PE2019000706A patent/PE20190609A1/es unknown
- 2017-09-25 HU HUE17781253A patent/HUE054898T2/hu unknown
- 2017-09-25 MX MX2019003492A patent/MX2019003492A/es unknown
- 2017-09-25 MA MA46342A patent/MA46342B1/fr unknown
- 2017-09-25 RS RS20210649A patent/RS61890B1/sr unknown
- 2017-09-25 AU AU2017334870A patent/AU2017334870C1/en active Active
- 2017-09-25 AR ARP170102642A patent/AR109714A1/es active IP Right Grant
- 2017-09-25 US US15/713,769 patent/US10335399B2/en active Active
- 2017-09-25 CR CR20190147A patent/CR20190147A/es unknown
- 2017-09-25 TN TNP/2020/000160A patent/TN2020000160A1/en unknown
- 2017-09-25 CA CA3037537A patent/CA3037537C/en active Active
- 2017-09-25 KR KR1020197011789A patent/KR102296043B1/ko active IP Right Grant
- 2017-09-25 SI SI201730727T patent/SI3519416T1/sl unknown
- 2017-09-25 MY MYPI2019001659A patent/MY196807A/en unknown
- 2017-09-25 JP JP2019516203A patent/JP6681517B2/ja active Active
- 2017-09-25 PT PT177812534T patent/PT3519416T/pt unknown
- 2017-09-25 LT LTEP17781253.4T patent/LT3519416T/lt unknown
-
2019
- 2019-03-13 IL IL265366A patent/IL265366B/en unknown
- 2019-03-19 ZA ZA2019/01701A patent/ZA201901701B/en unknown
- 2019-03-19 PH PH12019500597A patent/PH12019500597A1/en unknown
- 2019-03-20 NI NI201900025A patent/NI201900025A/es unknown
- 2019-03-22 CO CONC2019/0002673A patent/CO2019002673A2/es unknown
- 2019-03-25 CL CL2019000778A patent/CL2019000778A1/es unknown
- 2019-03-26 DO DO2019000076A patent/DOP2019000076A/es unknown
- 2019-03-28 EC ECSENADI201920742A patent/ECSP19020742A/es unknown
- 2019-04-23 US US16/392,131 patent/US10806724B2/en active Active
- 2019-09-30 JP JP2019178232A patent/JP6945605B2/ja active Active
-
2020
- 2020-03-23 JP JP2020051049A patent/JP6992109B2/ja active Active
- 2020-09-25 US US17/032,626 patent/US20210015800A1/en not_active Abandoned
- 2020-11-16 AU AU2020270468A patent/AU2020270468B2/en active Active
-
2021
- 2021-05-17 HR HRP20210793TT patent/HRP20210793T1/hr unknown
- 2021-05-31 CY CY20211100468T patent/CY1124346T1/el unknown
-
2022
- 2022-03-15 US US17/695,262 patent/US20220218676A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019000778A1 (es) | Derivados de cromano, isocromano y dihidroisobenzofuranos como moduladores alostéricos negativos de mglur2, composiciones y su uso. | |
| CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| ECSP18073366A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP19083621A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| UY37168A (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| NI201900099A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP18073293A (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
| UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
| NI201900098A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| ECSP13012967A (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2017001073A1 (es) | 2,4 diamino-quinolia sustituido como nuevos agentes anticancerigenos | |
| BR112015019412A8 (pt) | inibidores de bace1, seus usos, e composição farmacêutica | |
| CO7151509A2 (es) | Difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos como inhibidores de bace1 | |
| DOP2019000100A (es) | Derivados de naftiridinona y su uso en el tratamiento de la arritmia | |
| UY37622A (es) | Derivados de pirazol como inhibidores de bromodominio de la familia bet y su uso en aplicaciones terapéuticas | |
| CR20170426A (es) | Inhibidores de bace 1 | |
| BR112016007430A2 (pt) | 5-aril-1-imino-1-oxo-[1,2,4]tiadiazinas | |
| BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
| CO2022006718A2 (es) | Compuestos bicíclicos y métodos para su uso en el tratamiento del síndrome de pitt hopkins | |
| AR110598A1 (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| UA109669U (uk) | Фармацевтична композиція для лікування застудних захворювань у формі мазі |